Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alahist is a brand of over-the-counter (OTC) medications developed by Poly Pharmaceuticals for the symptomatic relief of allergies, the common cold, and cough. The product line includes several formulations such as Alahist IR, Alahist PE, Alahist CF, and Alahist DM. The primary active ingredient across the line is dexbrompheniramine maleate, a first-generation antihistamine that acts as an antagonist at the histamine H1 receptor to reduce symptoms like sneezing, rhinorrhea, and itchy/watery eyes. Depending on the specific formulation, Alahist products may also contain phenylephrine hydrochloride, a decongestant that targets alpha-1 adrenergic receptors, and dextromethorphan hydrobromide, a cough suppressant that acts as a sigma-1 receptor agonist and NMDA receptor antagonist. These medications are marketed for the temporary relief of upper respiratory symptoms associated with hay fever, allergic rhinitis, and the common cold.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alahist.